Extended Data Fig. 6: ILB predicts favorable survival outcomes in NPC cohorts. | Nature Medicine

Extended Data Fig. 6: ILB predicts favorable survival outcomes in NPC cohorts.

From: The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment

Extended Data Fig. 6

a, Kaplan–Meier curves for OS, distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) in NPC patients receiving GP chemotherapy stratified by high (≥50%) versus low (<50%) tumor-infiltrating ILBs in Cohort_3 (n = 139). ILB was measured by in situ mIF analysis. Multivariable analysis was shown in Supplementary Table 7. b, Kaplan–Meier curves for OS in all and subgroups of NPC patients stratified by high versus low expression of ILB signature in Cohort_2 (n = 150). Patients were dichotomously divided by median expression values. Multivariable analysis was shown in Supplementary Table 9. HRs and 95% CIs in a,b were calculated using a Cox regression model (two-sided P value by log-rank test).

Back to article page